NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Allogene Therapeutics, Inc. ALLO
8 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
—
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -190.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2024 · Operating -1241813.6% · Net -1170863.6%
ROE
FY2025 · ROE -53.4%
Each USD of equity lost 53 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | · |
| Operating income $B | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.3 | −0.2 | −0.2 |
| EBITDA $B | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.3 | −0.2 | −0.2 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 |
| Net income $B | −0.2 | −0.3 | −0.3 | −0.3 | −0.2 | −0.3 | −0.2 | −0.2 |
| Free cash flow $B | −0.1 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.2 | −0.0 |
| EPS, diluted $ | −0.87 | −1.32 | −2.09 | −2.38 | −1.34 | −2.63 | −1.83 | −7.31 |
| Dividend / sh $ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | −53.4 | −55.1 | −55.5 | −42.8 | −18.8 | −38.5 | −27.7 | −30.1 |
| Shares out B | 0.23 | 0.21 | 0.17 | 0.14 | 0.14 | 0.14 | 0.00 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 44 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2017